The goal of this study  is to understand how we can slow or reverse the emergence of AD symptoms

John Breitner, MD, has devoted his career to investigating factors that modify an individual’s risk of developing Alzheimer's Disease.

Giamal Luheshi investigates how IL-1 is involved in the initiation and progression of the inflammatory events associated with some brain disorders.

Judes Poirier who had discovered a novel genetic risk factor that triggers the common form of Alzheimer’s disease, again made history in June.  

Pedro Rosa-Neto is interested in the structural changes that occur in the brain as a result of neurodegenerative disease.

Work from Rémi Quirion's lab has helped to characterize the roles of cholinergic synapses in Alzheimer Disease, neuropeptide Y in depression and learning, and calcitonin gene-related peptide (CGRP) in pain and opioid tolerance.

Serge Gauthier has contributed to the development of new diagnostic and therapeutic approaches to Alzheimer's Disease and other dementing disorders.  

N.P. Vasavan Nair, M.D., FRCPC, has contributed to the Douglas Institute in a variety of capacities.

Sylvain Williams pursues several complimentary lines of study aimed towards elucidating the cause of Alzheimer Disease.

We all know that, as a population, we are getting older: By 2016, 17% of Canadians will be at least 65 years old and, as the population ages, the number of Alzheimer’s cases will rise accordingly (Statistics Canada) The risk of depression among caregivers of Alzheimer’s sufferers is twice as high as for informal caregivers of individuals with no dementia The needs of our aging population will be a heavy load to bear if we do not find more effective means to treat and prevent ...